Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus Durvalumab in Advanced Biliary Tract Cancers
NCT04781192Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Mar 2022
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, durvalumab in biliary tract cancer (BTC), sponsored by University of Kansas Medical Center. Started Mar 2022; status: active, not recruiting.
02
Drugs
regorafenibdurvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04781192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781192.